Clinical trial update: focus on the ONTARGET study

References

• BerlTHunsickerLGLewisJBCardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathyAnn Intern Med2003138542912667024
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEdeZEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med2001345861911565518
   PubMed Web of Science ®Google Scholar
• BrownNJKumarSPainterCAACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over timeHypertension2002408596512468570
   PubMed Web of Science ®Google Scholar
• CarlbergBSamuelssonOHjalmar LindholmLAtenolol in hypertension: is it a wise choice?Lancet20043641684915530629
   PubMed Web of Science ®Google Scholar
• DagenaisGRPogueJFoxKAngiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trialsLancet2006368581816905022
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• DanchinNCucheratMThuillezCAngiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trialsArch Intern Med20061667879616606817
   PubMed Web of Science ®Google Scholar
• DemersCMcMurrayJJSvedbergKImpact of Candesartan in Preventing Myocardial Infarction: Results of the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) ProgrammeCirculation2004110Suppl IIIIII514
   Google Scholar
• DeRosaGRagonesiPDMugelliniAEffects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double- blind, placebo-controlled 12-month studyHypertens Res2004274576415302981
   PubMed Web of Science ®Google Scholar
• DolFMartinGStaelsBAngiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient miceJ Cardiovasc Pharmacol20013839540511486244
   PubMed Web of Science ®Google Scholar
• DzauVJTissue angiotensin and the pathobiology of vascular disease: a unifying hypothesisHypertension20013710475211304501
   PubMed Web of Science ®Google Scholar
• DzauVJThe cardiovascular continuum and renin-angiotensin-aldosterone system blockadeJ Hypertens200523Suppl 1S9S17
   Google Scholar
• DzauVJMechanism of protective effects of ACE inhibition on coronary artery diseaseEur Heart J199819Suppl JJ2J69796834
   PubMedGoogle Scholar
• FlatherMDYusufSKoberLLong-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group [see comments]Lancet200035515758110821360
   PubMed Web of Science ®Google Scholar
• GrafeMAuch-SchwelkWZakrzewiczAAngiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectinCirc Res199781804119351454
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet2003362772613678870
   PubMed Web of Science ®Google Scholar
• HoriuchiMAkishitaMDzauVJRecent progress in Angiotensin type 2 receptor research in the cardiovascular systemHypertension199933621
   Web of Science ®Google Scholar
• HornigBKohlerCDrexlerHRole of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humansCirculation1997951115189054837
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436320223115207952
   PubMed Web of Science ®Google Scholar
• KimMPZhouMWahlLMAngiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque ruptureJ Leukoc Biol20057819520115817699
   PubMed Web of Science ®Google Scholar
• KurtzTWPravenekMAntidiabetic mechanisms of ACE inhibitors and AII receptor antagonists: beyond the renin-angiotensin systemJ Hypertens20042222536115614015
   PubMed Web of Science ®Google Scholar
• LevyBICan angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implicvations for the therapeutic blockade of the renin angiotensin systemCirculation200410981314707017
   PubMed Web of Science ®Google Scholar
• MatsubaraHPathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseaseCirc Res1998831182919851935
   PubMed Web of Science ®Google Scholar
• McKelvieRSYusufSPericakDComparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study InvestigatorsCirculation199910010566410477530
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet20033627677113678869
   PubMed Web of Science ®Google Scholar
• MurpheyLVaughanDBrownNContribution of bradykinin to the cardioprotective effects of ACE inhibitorsEuro Heart J Suppl20035Suppl AA37A41
   Web of Science ®Google Scholar
• OhishiMUedaMRakugiHRelative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesionsJ Hypertens1999175475310404957
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBrochnerMThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med2001345870811565519
   PubMed Web of Science ®Google Scholar
• PfefferMABraunwaldEMoyeLAEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after f infarction. Results of the survival and ventricular enlargement trial. The SAVE InvestigatorsN Engl J Med1992327669771386652
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003a349189390614610160
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet2003b3627596613678868
   PubMed Web of Science ®Google Scholar
• RutherfordJDPfefferMAMoyeLAEffects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE InvestigatorsCirculation199490173187923656
   PubMed Web of Science ®Google Scholar
• StraussMHHallASAngiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradoxCirculation20061148385416923768
   PubMed Web of Science ®Google Scholar
• StrehlowKWassermanSBohmMAngiotensin AT1 receptor over expression in hypercholesterolemiaAnn Med200032386911028685
   PubMed Web of Science ®Google Scholar
• TeoKYusufSSleightPRationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trialsAm Heart J2004148526115215792
   PubMed Web of Science ®Google Scholar
• The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease InvestigatorsEfficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPAstudy)Lancet2003362782813678872
   PubMed Web of Science ®Google Scholar
• The PEACE InvestigatorsAngiotensin-Converting–Enzyme Inhibitionin Stable Coronary Artery DiseaseN Engl J Med200435120586815531767
   PubMed Web of Science ®Google Scholar
• The SOLVD InvestigatorsEffect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractionsN Engl J Med1992327685911463530
   PubMed Web of Science ®Google Scholar
• TurnbullFNealBAlgertCBlood Pressure Lowering Treatment Trialists’ CollaborationEffects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trialsArch Intern Med20051651410915983291
   PubMed Web of Science ®Google Scholar
• VaughanDEAngiotensin, fibrinlysis and vascular homeostasisAm J Cardiol20018724
   Web of Science ®Google Scholar
• VerdecchiaPReboldiGAngeliFAngiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention [In Process Citation]Hypertension2005463869216009786
   PubMed Web of Science ®Google Scholar
• WagenaarLJVoorsAABuikemaHAngiotensin receptors in the cardiovascular systemCan J Cardiol2002181339
   Web of Science ®Google Scholar
• YusufSSleightPPogueJEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med20003421455310639539
   PubMed Web of Science ®Google Scholar